The update is based on continued positive data with vididencel in acute myeloid leukemia (AML) and follows the recent appointment of Tariq Mughal as Chief Medical Officer, describes the company.

“Rather than focusing on a limited patient population, our updated late-stage clinical development strategy in AML addresses the full spectrum of post-remission therapy in AML,” says Tariq Mughal. “As an immunotherapy, vididencel acts across different subtypes of AML and independent of specific AML mutations. With a stellar safety profile and supported by robust preclinical research data, vididencel can be combined with current and upcoming AML backbone therapies. This will allow us to broaden the addressable patient population and next decide the optimal path towards market entry, validated by input from the medical-scientific community and industry feedback.”

Reduce its staff from 28 to 19

Mendus also announced development of vididencel as an active immunotherapy for chronic myeloid leukemia (CML) and its dedicated focus on the clinical development of vididencel, including organizational changes to offset new clinical trial expenses.

Mendus will reduce its staff from 28 to 19, including an adjustment of the company’s executive management team from 5 to 3 members. With the large-scale production process and manufacturing alliance with NorthX Biologics accomplished, Chief Technology Officer Leopold Bertea will step down from the management team after a short transition period. Chief Scientific Officer Alex Karlsson-Parra will also step down and continue to act as adviser to Chief Medical Officer Tariq Mughal, who will take on the combined position of Chief Medical and Scientific Officer. Erik Manting and Lotta Ferm will remain Chief Executive Officer and Chief Financial Officer, respectively. The cost savings realized by the corporate reorganization are estimated to offset the extra trial costs anticipated for 2026, states the company.